Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O00148

UPID:
DX39A_HUMAN

ALTERNATIVE NAMES:
DEAD box protein 39; Nuclear RNA helicase URH49

ALTERNATIVE UPACC:
O00148; B1Q2N1; Q8N5M0; Q9BVP6; Q9H5W0

BACKGROUND:
The protein ATP-dependent RNA helicase DDX39A, known alternatively as DEAD box protein 39 and Nuclear RNA helicase URH49, is integral to the process of pre-mRNA splicing and mRNA export from the nucleus. Its activity is crucial for the proper functioning of gene expression mechanisms, highlighting its importance in cellular biology.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ATP-dependent RNA helicase DDX39A holds promise for identifying new therapeutic avenues. Given its critical role in mRNA processing, targeting this protein could lead to innovative treatments for conditions associated with gene expression abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.